EfficacySGR-1505 demonstrated a 22% overall response rate for 45 efficacy-evaluable patients across doses, with the strongest response seen in Waldenström macroglobulinemia patients.
Pipeline StrengthThe data support its therapeutic potential in B-cell malignancies and reinforce the strength of SDGR’s pipeline.
SafetyThe safety profile of SGR-1505 remained largely consistent and favorable compared to competing treatments, with some adverse events but no severe bilirubin increases.